Perosphere Inc., of Danbury, Conn., said it inked a third collaboration with Daiichi Sankyo Inc., of Tokyo, to study PER977, Perosphere's investigational anticoagulant reversal agent, in phase III registration studies with edoxaban, Daiichi's oral, once-daily, direct factor Xa-inhibitor.